Hepatitis C virus
BSIP | UIG | Getty Images
The overwhelming majority of individuals within the U.S. who’ve tested positive for hepatitis C haven’t been cured on account of the high cost of oral antiviral treatments and obstacles imposed by insurance policy, federal health officials said on Thursday.
Hepatitis C is also known as the silent killer since the initial infection has few to no symptoms. Additional time, nonetheless, the virus could cause liver damage, liver cancer, liver failure and ultimately death.
The virus is spread through contact with an infected person’s blood, primarily through sharing needles and other equipment used to inject drugs.
Breakthrough oral antiviral treatments made by Gilead Sciences and Abbvie have been on the U.S. marketplace for nearly a decade now. These pills, taken once a day for eight to 12 weeks, cure greater than 95% of hepatitis C cases.
Despite the provision of those medications, only one-third of the 1 million adults within the U.S. who tested positive for hepatitis C between 2013 and 2022 have been cured, in accordance with a report from the Centers for Disease Control and Prevention published Thursday. Health officials estimate up to a different million people within the U.S. are infected but do not know they’ve the virus.
Hepatitis C contributed to the deaths of nearly 15,000 people in 2020, in accordance with the CDC.
“Hundreds of persons are dying every yr in our country, and plenty of more are affected by an infection that has been curable for greater than 10 years,” Dr. Jonathan Mermin, director of the CDC division that makes a speciality of HIV and viral hepatitis, told reporters on a call Thursday.
The Biden administration has asked Congress to approve $11 billion in funding for a national program to eliminate hepatitis C by 2030. Dr. Francis Collins, who’s leading the initiative on the White House, said this system will save 1000’s of lives and pay for itself by reducing health care costs.
Medical health insurance and hepatitis care costs
Health officials said the first obstacles to treatment are requirements imposed by medical health insurance plans and the high cost of treatment. The course of pills can cost as much as $24,000 per patient.
Dr. Carolyn Wester, who heads the CDC’s viral hepatitis division, said some health insurers require burdensome preauthorization before patients can receive the pills and likewise limit which health-care providers can prescribe the medications.
Collins, who previously served as director of the National Institutes of Health, said community health centers that treat the uninsured cannot afford the pills for everybody. Only one in 4 uninsured adults diagnosed with hepatitis C have been cured, in accordance with the CDC.
Even state Medicaid plans impose burdensome requirements equivalent to evidence of liver disease, sobriety and the involvement of specialists, Collins told reporters on Thursday. The high cost of the drugs has made it difficult for Medicaid to treat everyone who’s infected, in accordance with the U.S. Health and Human Services Department.
Under Biden’s proposal, the federal government would pay pharmaceutical corporations like Gilead and Abbvie a lump sum for the drugs. The businesses would then make the medications available free of charge to the uninsured, state Medicaid programs, prison systems and folks living on Native American reservations.
The proposal relies on a model launched by Louisiana in 2019, through which the state paid Gilead subsidiary Asegua Therapeutics a lump sum for enough drugs over five years to cure nearly all Medicaid patients and people who find themselves incarcerated.
Collins said NIH and the Food and Drug Administration are also working on the approval of a rapid hepatitis C test that will provide a diagnosis in an hour or less. The test can be used to diagnose and treat patients in a single visit, he said.
